{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:13:43Z","timestamp":1788718423726,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010252","name":"\u015al\u0105ski Uniwersytet Medyczny w Katowicach","doi-asserted-by":"publisher","award":["PCN-1\u2013161\/N\/2\/K"],"award-info":[{"award-number":["PCN-1\u2013161\/N\/2\/K"]}],"id":[{"id":"10.13039\/501100010252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010252","name":"\u015al\u0105ski Uniwersytet Medyczny w Katowicach","doi-asserted-by":"publisher","award":["PCN-1\u2013203\/K\/0\/K"],"award-info":[{"award-number":["PCN-1\u2013203\/K\/0\/K"]}],"id":[{"id":"10.13039\/501100010252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010252","name":"\u015al\u0105ski Uniwersytet Medyczny w Katowicach","doi-asserted-by":"publisher","award":["PCN-2\u2013077\/N\/1\/K"],"award-info":[{"award-number":["PCN-2\u2013077\/N\/1\/K"]}],"id":[{"id":"10.13039\/501100010252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.105004","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:58:36Z","timestamp":1694447916000},"page":"105004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6987-1846","authenticated-orcid":false,"given":"Maria","family":"Nowak-Kiczmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Niedziela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenon P.","family":"Czuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Sowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wierzbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Lubczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Adamczyk-Sowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105004_bib0016","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41433-019-0693-7","article-title":"Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis","volume":"34","author":"Abu El-Asrar","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.msard.2023.105004_bib0010","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.12659\/MSM.895702","article-title":"Changes in serum ceruloplasmin levels based on immunomodulatory treatments and melatonin supplementation in multiple sclerosis patients","volume":"22","author":"Adamczyk-Sowa","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.msard.2023.105004_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190252","article-title":"Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"13","author":"Agah","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2023.105004_bib0042","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1742-2094-9-215","article-title":"Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis","volume":"9","author":"Romme Christensen","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105004_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103317","article-title":"Employment among patients with multiple sclerosis-a population study","volume":"9","author":"B\u00f8e Lunde","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2023.105004_bib0019","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1006\/cyto.2000.0734","article-title":"Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells","volume":"12","author":"Barill\u00e9","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.msard.2023.105004_bib0052","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/00207454.2020.1784167","article-title":"BAFF serum and CSF levels in patients with multiple sclerosis and infectious nervous system diseases","volume":"131","author":"Braun","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2023.105004_bib0026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fimmu.2017.00321","article-title":"Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"8","author":"Clemente","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.105004_bib0028","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jneuroim.2004.09.004","article-title":"Plasma osteopontin levels in multiple sclerosis","volume":"158","author":"Comabella","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/039463201002300119","article-title":"Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients","volume":"23","author":"Contasta","year":"2010","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.msard.2023.105004_bib0001","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive multiple sclerosis: new insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105004_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.683687","article-title":"Expression of IL-20 receptor subunit \u03b2 is linked to EAE neuropathology and CNS neuroinflammation","volume":"15","author":"Dayton","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.msard.2023.105004_bib0038","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1212\/WNL.47.1.123","article-title":"Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment","volume":"47","author":"Durelli","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105004_bib0022","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1093\/brain\/awm206","article-title":"Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients","volume":"130","author":"Dutta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.105004_bib0048","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.abd.2020.11.007","article-title":"Enhanced serum interferon-lambda 1 interleukin-29 levels in patients with psoriasis vulgaris","volume":"96","author":"Fu","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.msard.2023.105004_bib0021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.msard.2023.105004_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7057303","article-title":"Chemokines and growth factors produced by lymphocytes in the incompetent great saphenous vein","volume":"2019","author":"Grudzi\u0144ska","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.msard.2023.105004_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.615898","article-title":"Interleukin-19 abrogates experimental autoimmune encephalomyelitis by attenuating antigen-presenting cell activation","volume":"12","author":"Horiuchi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.105004_bib0024","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbi.2013.08.009","article-title":"The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis","volume":"35","author":"Iaffaldano","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.msard.2023.105004_bib0013","first-page":"12","article-title":"The effects of 21-day general rehabilitation after hip or knee surgical implantation on plasma levels of selected interleukins, VEGF, TNF-\u03b1, PDGF-BB, and eotaxin-1","author":"Idzik","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.msard.2023.105004_bib0009","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00415-019-09489-5","article-title":"A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition","volume":"268","author":"Inojosa","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105004_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2023.105004_bib0043","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-13-9367-9","author":"Jin","year":"2019","journal-title":"Structural Immunology"},{"key":"10.1016\/j.msard.2023.105004_bib0047","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2016.08.002","article-title":"The role of IL-29 in immunity and cancer","volume":"106","author":"Kelm","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.msard.2023.105004_bib0008","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.msard.2019.01.033","article-title":"Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: the impact of immune-related genes variability","volume":"29","author":"Kiselev","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105004_bib0007","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2023.105004_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1600-0404.2001.103002105.x","article-title":"Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity","volume":"103","author":"Laske","year":"2001","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2023.105004_bib0012","first-page":"11","article-title":"Association of metabolically healthy and unhealthy obesity phenotype with markers related to obesity, diabetes among young, healthy adult men. Analysis of MAGNETIC study","author":"Lejawa","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.msard.2023.105004_bib0006","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2023.105004_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071712","article-title":"Changes in cerebrospinal fluid balance of TNF and TNF receptors in na\u00efve multiple sclerosis patients: early involvement in compartmentalised intrathecal inflammation","volume":"10","author":"Magliozzi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.msard.2023.105004_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/817238","article-title":"Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review","volume":"2015","author":"McKay","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.msard.2023.105004_bib0018","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.51.4.1156","article-title":"Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis","volume":"51","author":"McMillan","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105004_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1759-1961.2011.00019.x","article-title":"Osteopontin and multiple sclerosis: an update","volume":"2","author":"Niino","year":"2011","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0005","first-page":"736","article-title":"Progressive multiple sclerosis","volume":"25","author":"Ontaneda","year":"2019","journal-title":"Continuum"},{"key":"10.1016\/j.msard.2023.105004_bib0023","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0165-5728(99)00120-4","article-title":"CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis","volume":"99","author":"Padberg","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0036","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001622-200311000-00005","article-title":"Interferons: mechanisms of action and clinical applications","volume":"15","author":"Parmar","year":"2003","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.msard.2023.105004_bib0031","first-page":"24","article-title":"Intrathecal versus peripheral inflammatory protein profile in ms patients at diagnosis: a comprehensive investigation on serum and CSF","author":"Pezzini","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2023.105004_bib0051","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2010.01.011","article-title":"Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis","volume":"220","author":"Piazza","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0165-5728(99)00146-0","article-title":"Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis","volume":"101","author":"Pickard","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0053","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2016.05.013","article-title":"BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset","volume":"297","author":"Puthenparampil","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0020","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bbamcr.2016.03.018","article-title":"The role of interleukin-6 signaling in nervous tissue","volume":"1863","author":"Rothaug","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.msard.2023.105004_bib0039","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cytogfr.2010.09.002","article-title":"Biology of interleukin-10","volume":"21","author":"Sabat","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.msard.2023.105004_bib0014","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13696998.2016.1277229","article-title":"Employment and absenteeism in working-age persons with multiple sclerosis","volume":"20","author":"Salter","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2023.105004_bib0037","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmhg.2011.06.009","article-title":"Serum interferon-alpha level in first degree relatives of systemic lupus erythematosus patients: correlation with autoantibodies titers","volume":"12","author":"Shahin","year":"2011","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.msard.2023.105004_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577385","article-title":"12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate","volume":"348","author":"Signoriello","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105004_bib0004","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00415-009-0039-7","article-title":"Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities","volume":"256","author":"Tremlett","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105004_bib0049","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.msard.2023.105004_bib0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2023.105004_bib0029","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1352458512457845","article-title":"Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica","volume":"19","author":"Wang","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105004_bib0046","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000464135","article-title":"Cytokine and chemokine profiles in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Wang","year":"2016","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.msard.2023.105004_bib0041","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjms.2018.08.018","article-title":"The properties of cytokines in multiple sclerosis: pros and cons","volume":"356","author":"Wang","year":"2018","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.msard.2023.105004_bib0034","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00415-012-6622-3","article-title":"Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis","volume":"260","author":"Wipfler","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105004_bib0002","doi-asserted-by":"crossref","first-page":"e16932","DOI":"10.2196\/16932","article-title":"A physician-completed digital tool for evaluating disease progression (multiple sclerosis progression discussion tool): validation study","volume":"22","author":"Ziemssen","year":"2020","journal-title":"J. Med. Internet Res."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:04:33Z","timestamp":1727453073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":53,"alternative-id":["S2211034823005059"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105004","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105004"}}